Acquisition history Aegis Therapeutics was acquired by Neurelis in December 2018, signaling integration into a broader neuroscience and drug delivery ecosystem. This history suggests potential alignment with parent company strategies and vested interests in scalable delivery platforms.

Intravail platform Core technology enables non-invasive delivery of proteins, peptides, and some small molecules via oral, buccal, and intranasal routes with high bioavailability, creating opportunities to license or co-develop formulations that expand administration options for injectable therapies.

ProTek stability ProTek excipients address protein stability and reduce immunogenicity while mitigating oxidative damage from polysorbates, presenting a compelling value proposition for biopharma partners seeking safer, more stable injectable alternatives.

Small team leverage With a lean team of 2–10 employees, there is potential to engage in partnerships, licensing deals, and outsourced programs to scale business development efforts without heavy internal overhead.

Limited revenue base Reported revenue is under one million dollars, which may present an opportunity for early-stage collaborations, milestones-driven partnerships, and co-development arrangements to accelerate market entry and de-risk investments.